<DOC>
	<DOCNO>NCT00055874</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor bone marrow transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . Also , imatinib mesylate may stop growth cancer cell block enzymes need cancer cell growth . Interferon alfa may interfere growth cancer cell slow growth cancer . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . It yet know treatment regimen effective treat chronic phase chronic myelogenous leukemia . PURPOSE : This randomized phase III trial study imatinib mesylate without interferon alfa cytarabine see well work compare interferon alfa follow donor stem cell transplant treat patient newly diagnose chronic phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Imatinib Mesylate With Without Interferon Alfa Cytarabine Compared With Interferon Alfa Followed Donor Stem Cell Transplant Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare hematologic , cytogenetic , molecular response rate patient newly diagnose chronic phase chronic myelogenous leukemia treat imatinib mesylate alone interferon alfa low-dose cytarabine v interferon alfa standard therapy . - Compare group-dependent , progression-free overall survival time progression patient treat regimen . - Compare efficacy allogeneic stem cell transplantation v imatinib mesylate-based therapy patient eligible transplantation . - Compare efficacy reduced-intensity conditioning vs standard conditioning patient 45 year age . - Determine time duration hematologic , cytogenetic , molecular response correlate factor patient treat regimen . - Compare short- long-term adverse effect regimens patient . - Compare presentation , duration , responses therapy accelerate blastic phase patient treat regimen . - Determine survival high-risk patient early allografting . - Determine influence pre-transplantation therapy outcome allogeneic stem cell transplantation patient . OUTLINE : This randomize , multicenter , pilot study . Patients stratify accord participate center . Patients low- intermediate-risk disease randomize 1 4 treatment arm . Patients high-risk disease randomize 1 3 treatment arm imatinib mesylate-based regimen . - Arm I : Patients receive oral imatinib mesylate daily 12 month absence disease progression unacceptable toxicity . - Arm II : Patients receive oral imatinib mesylate arm I . Patients also receive interferon alfa subcutaneously ( SC ) 3 time week begin least 3 month start imatinib mesylate . - Arm III : Patients receive oral imatinib mesylate arm I . Patients also receive cytarabine SC twice daily 5 day monthly begin least 3 month start imatinib mesylate . - Arm IV : After initial cytoreduction hydroxyurea , patient receive interferon alfa SC daily without hydroxyurea . In absence complete response 3 month , patient may also receive low-dose cytarabine SC daily . Treatment continue 21 month . Patients fail interferon alfa therapy cross receive imatinib mesylate . Patients fail therapy imatinib mesylate eligible allogeneic transplantation stratify accord availability donor ( HLA-identical relate v unrelated ) , status , participate center . Patients randomize receive allogeneic transplantation continue salvage therapy . Patients eligible allogeneic transplantation receive hydroxyurea cytarabine high-dose chemotherapy autologous stem cell rescue follow interferon- imatinib mesylate-based therapy . Patients 45 year age randomize receive age-adjusted standard condition regimen reduce intensity preparative regimen ( mini transplantation ) prior allogeneic transplantation . Patients follow every 6 month 3 year annually thereafter . PROJECTED ACCRUAL : A total 1,600 patient ( 400 per treatment arm ) accrue study within 4-5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose chronic phase chronic myelogenous leukemia ( CML ) bcrabl positive No blast , promyelocytes , myelocyte , metamyelocytes peripheral blood Availability HLAidentical sibling unrelated donor PATIENT CHARACTERISTICS : Age Any age Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing Fertile patient must use effective contraception No second malignancy require therapy No evidence diseaserelated symptom extramedullary disease ( include hepatosplenomegaly ) No serious disease would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No prior interferon Chemotherapy No prior chemotherapy hydroxyurea Endocrine therapy Not specify Radiotherapy No prior radiotherapy Surgery Not specify Other Prior anagrelide allow No participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
</DOC>